NYSE$AVNS
Avanos Medical Inc · Q4 2025 earnings
Q4 2025 earnings · · Before market open · Investor relations
Briefing
Avanos Medical reported Q4 2025 net sales of $180.9M with adjusted diluted EPS of $0.29.
Fourth-quarter net sales rose 0.7% to $180.9 million. GAAP net loss was $1.3 million ($0.03 per share) versus a large prior-year loss tied to goodwill impairment; adjusted net income was $13.4 million ($0.29 EPS). Specialty Nutrition Systems sales grew 8.7% to $115.1 million. Management guided 2026 net sales of $700–720 million and adjusted EPS of $0.90–$1.10.
- Q4 net sales $180.9M (+0.7% YoY); SNS segment +8.7%.
- Adjusted diluted EPS $0.29; adjusted EBITDA $28.0M.
- 2026 sales guide $700M–$720M; transformation savings $15M–$20M.
- Full-year organic growth 6% in strategic segments.
Headline financials
Revenue & EPS history
Avanos · Revenue · Quarterly
$181M
Forward guidance
2026 net sales guidance of $700M–$720M and adjusted diluted EPS of $0.90–$1.10; transformation savings target $15M–$20M annualized by end of 2026.
Tailwinds
- Full-year organic growth of 6% in strategic SNS and PM&R segments.
- Tariff mitigation on track; cost management initiatives gaining traction.
- Net debt reduced to $10.7M at year-end.
Headwinds
- GAAP net loss and prior-year goodwill impairment overhang.
- Q4 free cash flow down versus prior year.
- Macro and regulatory risks for medical devices.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2025
-0.7%
Avg return
Earnings day
-1.1%
Avg return
5 days after
-1.7%
Avg return
30 days after
50%
25 / 50 earnings
Positive
+17.2%
Q3 2023
Best reaction
-27.6%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.1% | +0.5% | +1.3% | |
| Q4 2025 | -11.0% | -7.4% | -9.1% | |
| Q3 2025 | -1.2% | -3.3% | +1.4% | |
| Q1 2025 | +5.6% | +3.8% | +1.1% | |
| Q4 2024 | +0.4% | -2.8% | -10.3% | |
| Q3 2024 | -17.5% | -15.1% | -15.3% | |
| Q2 2024 | +3.4% | -0.0% | +5.5% | |
| Q1 2024 | +4.7% | +4.0% | +6.0% | |
| Q4 2023 | +1.7% | +2.6% | +1.6% | |
| Q3 2023 | +17.2% | +18.3% | +20.3% | |
| Q2 2023 | -2.1% | -5.8% | -15.4% | |
| Q1 2023 | -18.7% | -19.0% | -14.3% | |
| Q4 2022 | -2.7% | -4.3% | -6.5% | |
| Q3 2022 | -0.1% | +7.2% | +20.9% | |
| Q2 2022 | -1.3% | +1.8% | -13.4% | |
| Q1 2022 | +0.9% | -12.0% | -3.8% | |
| Q4 2021 | +15.1% | +19.9% | +12.2% | |
| Q3 2021 | +12.8% | +9.7% | -4.6% | |
| Q2 2021 | -11.8% | -9.8% | -12.5% | |
| Q1 2021 | -8.2% | -10.0% | -8.6% | |
| Q4 2020 | -14.7% | -16.7% | -14.0% | |
| Q3 2020 | +9.2% | +7.2% | +17.4% | |
| Q2 2020 | -0.8% | +0.0% | +3.1% | |
| Q1 2020 | -4.2% | -6.3% | +10.0% | |
| Q4 2019 | +7.3% | +5.9% | -16.4% | |
| Q3 2019 | -27.6% | -24.9% | -30.4% | |
| Q2 2019 | -3.5% | +0.7% | -10.4% | |
| Q1 2019 | -6.3% | -3.8% | -13.8% | |
| Q4 2018 | -6.7% | -6.2% | -18.4% | |
| Q3 2018 | -15.5% | -13.8% | -21.9% | |
| Q2 2018 | +9.8% | +8.0% | +23.4% | |
| Q1 2018 | +8.0% | +9.6% | +15.9% | |
| Q4 2017 | +2.3% | -3.2% | -4.5% | |
| Q3 2017 | +11.5% | +9.9% | +14.9% | |
| Q2 2017 | +6.6% | +6.5% | +13.6% | |
| Q1 2017 | -7.0% | -5.0% | -6.5% | |
| Q4 2016 | -5.7% | -3.0% | -7.7% | |
| Q3 2016 | +0.7% | +6.6% | +16.4% | |
| Q2 2016 | +5.6% | +6.4% | +8.1% | |
| Q1 2016 | -2.2% | — | — | |
| Q4 2015 | +1.7% | — | — | |
| Q3 2015 | +4.6% | — | — | |
| Q2 2015 | -1.1% | — | — | |
| Q1 2014 | -2.4% | — | — | |
| Q1 2015 | +2.2% | — | — | |
| Q2 2014 | -0.3% | — | — | |
| Q4 2012 | -0.3% | — | — | |
| Q4 2014 | +3.7% | — | — | |
| Q3 2014 | +0.7% | — | — | |
| Q4 2013 | +0.7% | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro